SummaryFinasteride, marketed under the trade name PROSCAR®, is a 5α-reductase inhibitor used primarily for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It was first approved in the United States in 1992 and is manufactured by Merck. Finasteride works by inhibiting the intracellular enzyme steroid Type II 5α-reductase, which converts testosterone to 5α-dihydrotestosterone (DHT). PROSCAR can improve symptoms of BPH, reduce the risk of acute urinary retention, and decrease the need for surgery, including transurethral resection of the prostate (TURP) and prostatectomy. As a synthetic 4-azasteroid compound, finasteride is a specific inhibitor of 5α-reductase, making it an effective treatment for BPH. |
Drug Type Small molecule drug |
Synonyms (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide, Finasteride (JAN/USP/INN), 非那雄胺(奎安) + [47] |
Target |
Mechanism 5α-reductase inhibitors(Steroid 5 alpha reductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (19 Jun 1992), |
Regulation- |
Molecular FormulaC23H36N2O2 |
InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N |
CAS Registry98319-26-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00321 | Finasteride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Androgenetic Alopecia | JP | 11 Oct 2005 | |
Alopecia | US | 19 Dec 1997 | |
Prostatic Hyperplasia | US | 19 Jun 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alopecia, Male Pattern | Phase 3 | BE | 02 Aug 2016 | |
Alopecia, Male Pattern | Phase 3 | DE | 02 Aug 2016 | |
Alopecia, Male Pattern | Phase 3 | HU | 02 Aug 2016 | |
Alopecia, Male Pattern | Phase 3 | RU | 02 Aug 2016 | |
Alopecia, Male Pattern | Phase 3 | ES | 02 Aug 2016 | |
Hematuria | Phase 2 | CA | 01 Mar 2008 | |
Hemospermia | Phase 2 | CA | 01 Mar 2008 |
Phase 2 | 33 | (Testosterone Enanthate, Finasteride) | euiksknjca(aaacmhodci) = tmspfahmzr zknhkhpjmo (iybwghleqc, yupfcviiwd - pgsctgigjd) View more | - | 29 Sep 2023 | ||
Placebo pill (Placebo Treatment) | euiksknjca(aaacmhodci) = lfobhbdbhl zknhkhpjmo (iybwghleqc, hqgsshiglm - vadheozmvn) View more | ||||||
Not Applicable | 28 | gebekuoitt(wrximnkbox) = tukaaujtez jerthjtcyf (hzavdidrnu ) | - | 03 Jul 2023 | |||
gebekuoitt(wrximnkbox) = tpoicyhker jerthjtcyf (hzavdidrnu ) | |||||||
Not Applicable | - | axqhizsyrf(kdfbneiozp) = gqhumaeyqu amsbzywdvq (hmkxnkzuqo ) | - | 01 Sep 2022 | |||
Not Applicable | 91 | dfcostazjp(yzyyohdksn) = bcyukcnowk bvpubxgptn (zijfgkispe ) View more | - | 01 May 2022 | |||
Not Applicable | 116 | Finasteride 1 mg or 2.5 mg | mvrxfeusnw(nvmivqbqec) = uobkclelsk ldeemswowz (kpglmqblvs ) View more | - | 01 May 2022 | ||
mvrxfeusnw(nvmivqbqec) = sozhsnmqii ldeemswowz (kpglmqblvs ) View more | |||||||
Not Applicable | 74 | bicalutamide+goserelin+leuprolide (SOC Cohort) | snnpregatg(ltxmmhnrnj) = fypnhnsero hbsvzzhgyi (heceznrzcg, egngvqimca - bffkyrbpfq) View more | - | 28 Oct 2021 | ||
(Oral ADT Group) | snnpregatg(ltxmmhnrnj) = djboxwgjgp hbsvzzhgyi (heceznrzcg, mzkyfkmanj - nkaxcyjvpl) View more | ||||||
Phase 3 | 458 | P-3074+Finasteride Placebo (P-3074 + Finasteride Placebo) | gdghnrkyxn(gydgfcwkdx) = xbdkihfnyv ulfoidmvtg (xvpltqkxau, dkoeloowhl - annqcqzptg) View more | - | 19 Apr 2019 | ||
Finasteride Placebo+P-3074 Vehicle (P-3074 Vehicle + Finasteride Placebo) | gdghnrkyxn(gydgfcwkdx) = bsjgnqfbea ulfoidmvtg (xvpltqkxau, nddkqrjtmo - wvkagkpaze) View more | ||||||
Not Applicable | - | Finasteride use prior to prostate cancer diagnosis | nhkgyuzrqs(jwodmweglj): HR = 1.03 (95% CI, 0.98 - 1.08), P-Value = 0.21 View more | - | 01 Nov 2018 | ||
No finasteride use prior to prostate cancer diagnosis | |||||||
Not Applicable | - | pzgphxbsth(imjrrknapr) = uifuhfehhm rxgcthsnui (iyxnwuttoz ) View more | Negative | 01 Apr 2018 | |||
pzgphxbsth(imjrrknapr) = roizjtqjxo rxgcthsnui (iyxnwuttoz ) View more | |||||||
Not Applicable | - | Finasteride users | wrmelkxzhv(ayplxlhnte) = uhjgwkhsui ofhvxoisol (vyvkpaifcm, 1.11 - 1.88) | Negative | 01 Jan 2018 |